

# Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT)

W.J. Wiersinga<sup>1\*</sup>, M.J. Bonten<sup>2</sup>, W.G. Boersma<sup>3</sup>, R.E. Jonkers<sup>4</sup>, R.M. Aleva<sup>5</sup>, B.J. Kullberg<sup>6</sup>, J.A. Schouten<sup>7</sup>, J.E. Degener<sup>8</sup>, E.M.W. van de Garde<sup>9</sup>, T.J. Verheij<sup>10</sup>, A.P.E. Sachs<sup>10</sup>, J.M. Prins<sup>1</sup>

<sup>1</sup>Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands, <sup>2</sup>Department of Medical Microbiology, University Medical Center, Utrecht, the Netherlands, <sup>3</sup>Department of Pulmonary Diseases, Northwest Hospital Group, Alkmaar, the Netherlands, <sup>4</sup>Department of Respiratory Medicine, Academic Medical Centre, Amsterdam, the Netherlands, <sup>5</sup>Department of Pulmonary Diseases, Máxima Medical Center, Eindhoven, the Netherlands, <sup>6</sup>Radboud Center for Infectious Diseases and Department of Internal Medicine, Radboudumc, Nijmegen, the Netherlands, <sup>7</sup>Department of Intensive Care, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands, <sup>8</sup>Department of Medical Microbiology, University Medical Center, Groningen, the Netherlands, <sup>9</sup>Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, the Netherlands, Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands, <sup>10</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands, \*corresponding author: email: w.j.wiersinga@amc.uva.nl

## ABSTRACT

The Dutch Working Party on Antibiotic Policy in collaboration with the Dutch Association of Chest Physicians, the Dutch Society for Intensive Care and the Dutch College of General Practitioners have updated their evidence-based guidelines on the diagnosis and treatment of community-acquired pneumonia (CAP) in adults who present to the hospital. This 2016 update focuses on new data on the aetiological and radiological diagnosis of CAP, severity classification methods, initial antibiotic treatment in patients with severe CAP and the role of adjunctive corticosteroids. Other parts overlap with the 2011 guideline. Apart from the Q fever outbreak in the Netherlands (2007-2010) no other shifts in the most common causative agents of CAP or in their resistance patterns were observed in the last five years. Low-dose CT scanning may ultimately replace the conventional chest X-ray; however, at present, there is insufficient evidence to advocate the use of CT scanning as the new standard in

patients evaluated for CAP. A pneumococcal urine antigen test is now recommended for all patients presenting with severe CAP; a positive test result can help streamline therapy once clinical stability has been reached and no other pathogens have been detected. Coverage for atypical microorganisms is no longer recommended in empirical treatment of severe CAP in the non-intensive care setting. For these patients (with CURB-65 score  $\geq 2$  or Pneumonia Severity Index score of 5) empirical therapy with a 2nd/3rd generation cephalosporin is recommended, because of the relatively high incidence of Gram-negative bacteria, and to a lesser extent *S. aureus*. Corticosteroids are not recommended as adjunctive therapy for CAP.

## KEYWORDS

Antimicrobial therapy, community-acquired pneumonia, guidelines

## INTRODUCTION

Community-acquired pneumonia (CAP) is defined as an acute symptomatic infection of the lower respiratory tract in patients outside a hospital or a long-term care facility, whereby a new infiltrate is demonstrated.<sup>1,2</sup> CAP is a common condition that carries a high burden of mortality and morbidity, particularly in the elderly.<sup>2,3</sup> In the Netherlands, approximately 250,000 patients develop pneumonia each year (<https://www.volksgezondheidenzorg.info>, 2 August 2017). This translates into an incidence of 15 per 1000 person-years. Worldwide, CAP remains the second cause of death and life years lost.<sup>3</sup>

The Dutch Working Party on Antibiotic Policy (SWAB; Stichting Werkgroep Antibiotica Beleid), established by the Dutch Society for Infectious Diseases (VIZ), the Dutch Society for Medical Microbiology (NVMM) and the Dutch Society for Hospital Pharmacists (NVZA), coordinates activities in the Netherlands aimed at optimising antibiotic use, and containment of the development of antimicrobial resistance. In 2011 the SWAB and the Dutch Association of Chest Physicians (NVALT) published a joint guideline on the management of CAP. The present guideline is an update of this guideline, prepared by SWAB in collaboration with NVALT, the Dutch Society of Intensive Care (NVIC), and the Dutch College of General Practitioners (NHG).<sup>1</sup> See *textbox 1* for the methods.

### Textbox 1

#### Methods and systemic literature review

The methods were identical to those of the previous version of these guidelines.<sup>1</sup> In short, these guidelines were drawn up according to the EBRO (Evidence Based Richtlijn-Ontwikkeling) and AGREE (Appraisal of Guidelines Research and Evaluation) recommendations for the development of guidelines.<sup>43</sup> A review of the existing national and international guidelines<sup>24,25</sup> was performed in addition to a literature search in PubMed database, Cochrane Register of Controlled Trials (CENTRAL), EMBASE, BMJ's Best Practice® and in Sumsearch® engine. For resistance surveillance data we utilised NethMap 2016.<sup>10</sup> Preparation of the guidelines text was carried out by a multidisciplinary committee consisting of experts delegated from the above-mentioned professional societies. After consultation with the members of the relevant professional societies, the definitive guidelines were drawn up by the delegates and approved by the boards of SWAB and NVALT. The full guidelines text, literature review and rebuttal of the received commentaries are available at [www.swab.nl](http://www.swab.nl).

Revision was considered necessary because in the past few years new – for a significant part Dutch – data have been published on the differences between the various disease severity classification systems on the percentage of patients treated as severe CAP, the sensitivity of chest computed tomography (CT scan) for diagnosis, the role of atypical coverage in patients with severe CAP, and the role of adjunctive prednisone therapy. Therefore, the Guideline committee decided to update the recommendations on imaging, empirical treatment, and the use of corticosteroids in CAP. It should be stressed that other parts of the guideline were not updated and show a large overlap with the previously published 2011 guideline.<sup>1</sup> This is indicated for the relevant sections. See *textbox 2* for a short summary of all the new recommendations compared with the 2011 guideline.

The CAP guideline focusses on the initial treatment of suspected CAP in adult patients who present to the hospital, and are treated as outpatients, and hospitalised patients up to 72 hours after admission. Pneumonia in immunocompromised patients is outside the scope of this guideline.

## CAUSATIVE BACTERIAL SPECIES OF CAP IN THE NETHERLANDS AND THEIR ANTIBIOTIC SUSCEPTIBILITY

*Streptococcus pneumoniae* remains the most commonly isolated bacterial pathogen causing CAP and should therefore always be covered in empirical treatment.<sup>1</sup> The annual number of registered *Legionella* infections in the Netherlands is stable at around 300 cases per year (<http://www.rivm.nl/Onderwerpen/L/Legionella>). From 2007 to 2010 the Netherlands experienced a large Q fever outbreak, caused by *Coxiella burnetii*, leading to a large number of hospital admissions, mostly for CAP, in those years. No other major shifts in the aetiology of CAP were observed in the last five years, although it should be emphasised that in up to half of CAP episodes no causative microorganism can be identified (*table 1*).<sup>4,7</sup> In patients with severe CAP and in patients who are admitted to the intensive care unit (ICU), *Legionella* spp., *Staphylococcus aureus* and Gram-negative infections are encountered more frequently compared with patients with mild to moderately severe CAP (*table 1*).<sup>4,7</sup> Recent retrospective data points to the need for increased awareness of *Aspergillus* infection as a complication of H1N1 influenza A virus infection in critically ill patients on the ICU.<sup>8</sup> It should be noted that the occurrence of atypical pathogens (*Legionella* spp., *C. burnetii*, *Mycoplasma pneumoniae*, and *Chlamydia/Chlamydophila* species) in patients admitted to the ward with a CURB-65 score of  $\geq 3$  is very low (*table 1*).<sup>9</sup>

The resistance percentage of *S. pneumoniae* for erythromycin is 12%, for co-trimoxazole 7% and for

## Textbox 2

- What's new since the 2011 guidelines were published? *S. pneumoniae* remains the most common isolated bacterial cause of CAP in the Netherlands. In patients with severe CAP or patients who must be admitted to the ICU, *Legionella* spp. (up to 6%), *S. aureus* (up to 10%) and Gram-negative infections (up to 20%) are encountered more frequently than in patients with mild or moderate severe CAP. No aetiological agent can be identified in up to half of the episodes of CAP. The large Q fever outbreak in the Netherlands, which started in 2007, came to an end in 2010. No major shifts in resistance patterns of the most common causative agents of CAP were observed in the past 5 years in the Netherlands.
- Patients with CAP may be classified according to severity: I) mild, II) moderately severe, III) severe CAP admitted to the ward and IV) severe CAP admitted to the intensive care unit (ICU). Two validated scoring systems are in use: the Pneumonia Severity Index and the CURB-65. Alternatively, a pragmatic classification (treatment at home; admission to a general medical ward and admission to ICU) can be used. The committee does not recommend any of these scoring systems over the others; however, we recommend that each hospital uses only one scoring system consistently in daily practice.
- For patients with risk category III (severe CAP – ward admission; CURB-65: 3-5; PSI: 5; hospitalised on non-ICU ward) therapy should be started with a 2nd or 3rd generation cephalosporin. No empirical coverage for atypical microorganisms is given. A *Legionella* and pneumococcal urinary antigen test should be carried out as a routine procedure within 12-24 hours of admission. If the *Legionella* test is positive, monotherapy directed against *Legionella* spp. is recommended. If the pneumococcal urinary antigen test is positive, therapy can be narrowed to penicillin or amoxicillin. If both are negative, therapy is continued with a 2nd or 3rd generation cephalosporin, to provide additional coverage for *Enterobacteriaceae* and to a lesser extent *S. aureus*.
- For patients with category IV (severe CAP – ICU admission; hospitalised on ICU ward) it is always recommended to cover *S. pneumoniae*, *Legionella* spp. and Gram-negative infections. For this purpose there are two equally acceptable choices, both with excellent antimicrobial activity against all expected causative agents: (a) monotherapy with moxifloxacin or (b) combination therapy with a 2nd or 3rd generation cephalosporin and ciprofloxacin. Macrolides are no longer recommended in this patient category. For all patients in category IV, a *Legionella* urinary antigen and *S. pneumoniae* urine antigen test is carried out as a routine procedure within 12-24 hours of admission. If the *Legionella* test is positive, monotherapy directed against *Legionella* spp. is recommended. If the *Legionella* test is negative, the patient is still treated further with combination therapy (coverage of both *S. pneumoniae* and *Legionella* spp.) because the sensitivity of the urinary antigen test is not 100%. Since the specificity of the pneumococcal urine antigen test is < 100%, antibiotic treatment can be streamlined to penicillin or amoxicillin only in patients with a positive test result and without another pathogen detected once clinical stability (often within 48 hours) has been reached.
- Corticosteroids are not recommended as adjunctive therapy for treatment of CAP.

doxycycline 9%.<sup>10</sup> Resistance to levofloxacin and moxifloxacin is very uncommon. In the Netherlands, high-level penicillin-resistant *S. pneumoniae* is extremely rare (< 1%) and thus does not require coverage by empirical antibiotic therapy. High-level resistance to penicillin should be considered in patients not – or insufficiently – responding to empirical treatment with penicillin or amoxicillin and with a recent travel history abroad. In such patients, increasing the dosage of penicillin or a switch to a cephalosporin should be considered.

## SEVERITY OF DISEASE UPON PRESENTATION IS USED FOR THE CHOICE OF INITIAL TREATMENT

Patients with CAP may be classified according to severity: mild, moderate-severe and severe CAP. Selection of empirical antibiotic therapy should be guided by the severity of the disease at presentation. Three scoring systems are in use. The Pneumonia Severity Index (PSI or Fine score) and the CURB-65 score (table 2)<sup>I,II-13</sup> are validated scoring systems, equally reliable in predicting

**Table 1.** Most common aetiologies of community-acquired pneumonia in the Netherlands according to study population

	Study population		
	Community	Hospital	ICU
	1 study <sup>4*</sup>	2 studies <sup>5-9</sup>	1 study <sup>7</sup>
<i>S. pneumoniae</i>	6%	8-24%	22%
<i>H. influenzae</i>	9%	3-5%	7%
<i>Legionella</i> spp.	0%	1-6%	1%
<i>S. aureus</i>	0%	1-2%	10%
<i>M. catarrhalis</i>	0%	0-1%	0%
<i>Enterobacteriaceae</i>	0%	2-5%	8%
<i>Pseudomonas aeruginosa</i>	0%	0-2%	5%
<i>M. pneumoniae</i>	9%	1-3%	0%
<i>Chlamydia</i> spp.	2%	0-7%	0%
<i>C. burnetii</i>	0%	0-14%	1%
Viral (e.g. Influenza)	37%	3-5%	17%
Other	2%	2-3%	10%
No pathogen identified	33%	63-65%	25%

Data on the hospital and intensive care unit study populations were derived from studies published between 2011 and 2016, data on the community were derived from a study published in 2004. \*This study included patients with a lower respiratory tract infection in general practice, no standard chest X-ray was performed for the diagnosis of CAP.

30-day mortality in patients hospitalised with CAP.<sup>14-16</sup> Alternatively, a pragmatic classification (treatment at home; admission to a general medical ward and admission to an ICU) can be used. It should be noted that there can be marked differences in the categorisation of severity using these different scoring systems. For instance, a Dutch study among 1047 patients admitted with CAP showed that using a CURB-65 score > 2 as cut-off, almost twice as many patients were classified as having severe CAP as compared with the PSI score.<sup>17</sup> However, with a cut-off CURB-65 score of > 3 less patients were classified as severe CAP compared with the PSI. As there is no gold standard, the committee does not recommend any of the scoring systems over the other; however, it is recommended that each hospital consistently uses only one of these scoring systems in daily practice. These recommendations are identical to the previous guideline.<sup>1</sup>

## RADIOLOGICAL INVESTIGATIONS IN THE DIAGNOSTIC WORK-UP OF PATIENTS SUSPECTED FOR CAP

The chest X-ray does not allow prediction of the causative microorganism in CAP.<sup>18,19</sup> The wider availability of low-dose CT scan facilities at emergency departments will

likely lead to increased use of CT scanning of the chest in patients presenting with respiratory symptoms, and may ultimately replace the conventional chest X-ray. Recent data show that an early CT scan can improve diagnostic accuracy compared with chest X-ray.<sup>20</sup> However, at present, there is not enough evidence to advocate the use of CT scanning as the new standard in patients evaluated for CAP. For patients with clinical features of CAP but without signs of infection on the initial chest X-ray, an additional chest X-ray within 48 hours may help to establish the diagnosis of CAP.<sup>21</sup>

## MICROBIOLOGICAL INVESTIGATIONS

Although interpretation of Gram's stain of sputum may allow early identification of the bacteriological cause of CAP, it is not recommended for guiding initial treatment. However, before starting antimicrobial therapy, blood and, if possible, sputum specimens should be obtained for culture, because culture results enable streamlining of antibiotic therapy and a switch to oral therapy if a specific pathogen is isolated. PCR results from nasopharyngeal swabs are considered the most reliable indicator for influenza virus replication in the human body.<sup>22,23</sup> Validated PCR tests for respiratory viruses and atypical

**Table 2.** Validated scoring systems to measure the severity of disease in patients with CAP: the CURB-65 and Pneumonia Severity Index<sup>1,11,12</sup>

CURB-65	<b>CURB-65 criteria</b>		
	Confusion: defined as a new disorientation in person, place or time		
	Urea > 7 mmol/l		
	Respiratory rate ≥ 30 / min		
	Blood pressure: Systolic blood pressure < 90 mmHg or diastolic blood pressure ≤ 60 mmHg		
	Age ≥ 65		
	<b>Core criteria</b>	<b>Score CURB-65</b>	<b>30-day mortality</b>
	No core criteria	0	0.7%
	One core criterion	1	3.2%
	Two core criteria	2	3%
Pneumonia Severity Index (PSI or Fine score)	<b>Step 1: Patient with community-acquired pneumonia</b>		
	If presence of <b>any</b> of the following proceed to step 2, if all are absent assign to risk class I: over 50 years of age; altered mental status; pulse ≥ 125/min; respiratory rate > 30/min; systolic blood pressure < 90 mmHg; temperature < 35°C or ≥ 40°C and/or a history of neoplastic disease, congestive heart failure, cerebrovascular disease, renal disease, liver disease		
	<b>Step 2: Point scoring system (Characteristic and points assigned)</b>		
	Age: Age in years (male); Age in years –10 (female)		
	Coexisting conditions: Neoplastic disease + 30; liver disease + 20; congestive heart failure + 10; cerebrovascular disease +10; renal disease + 10		
	Physical examination: Altered mental status + 20; respiratory rate ≥ 30 / min + 20; systolic blood pressure < 90 mmHg + 20; temperature < 35°C or ≥ 40°C + 15; pulse ≥ 125 / min + 10		
	Laboratory and radiological findings: arterial pH < 7.35 + 30; urea ≥ 11.0 mmol/l + 20; sodium < 130 mmol/l + 30; glucose ≥ 14.0 mmol/l + 10; haematocrit < 30% + 10; partial oxygen pressure < 60 mmHg + 10; pleural effusion + 10		
	<b>Step 3. Calculation of 30-day mortality</b>		
	<b>Risk class</b>	<b>Total score</b>	<b>Mortality</b>
	I	Not applicable	0.1%
	II	≤70	0.6%
	III	71-90	0.9%
	IV	91-130	9.3%
	V	>130	27.0%

pathogens are preferred over serological tests. A urinary antigen test for *Legionella* spp. should be performed in all patients with severe CAP.<sup>24-27</sup> One should, however, be aware that in the early stages of the disease the *Legionella* urinary antigen test may be falsely negative, especially in patients with mild pneumonia. In addition, with the current widely used test (immunochromatographic assay) only *L. pneumophila* type 1, which accounts for approximately 90% of *Legionella* cases, can be detected.

While the above recommendations have not changed compared with the previous guidelines,<sup>1</sup> the usefulness of the urinary pneumococcal antigen test has been reconsidered. The sensitivity of the urinary pneumococcal antigen test for demonstrating a causative role of *S. pneumonia* in adult patients is low, but the test is highly specific.<sup>28-31</sup> It has to be noted, however, that urinary pneumococcal antigens may be detectable in children, and also in adult patients with exacerbations of chronic obstructive pulmonary disease


without pneumonia.<sup>32</sup> It is now recommended to perform an urinary antigen test for *S. pneumoniae* in all patients treated for severe CAP. In patients with a positive test result and without another pathogen detected, antibiotic treatment can be simplified to amoxicillin or penicillin when the patient is treated on the ward. For patients on the ICU, therapy is de-escalated once clinical stability has been reached, which is often within 48 hours (figure 1).

## EMPIRICAL ANTIBIOTIC THERAPY FOR CAP

As compared with the previous guidelines, the most important change in the recommended empirical antibiotic

therapy for CAP is to start with 2nd or 3rd generation cephalosporin monotherapy instead of combination therapy with amoxicillin or penicillin together with a quinolone or erythromycin in patients with severe CAP who are treated in a non-ICU ward. From an antibiotic stewardship perspective this is an important gain. The main reason for this change is the very low incidence of atypical pathogens in patients admitted to the ward with CURB-65 score  $\geq 3$  as outlined above. This is supported by the recent findings from the Dutch CAP-START study, involving more than 2000 patients with clinically suspected CAP admitted to non-ICU wards; in this study empirical treatment with beta-lactam monotherapy was non-inferior to strategies with a beta-lactam-macrolide combination or 4th generation fluoroquinolone

**Figure 1.** Flow chart of guideline recommendations on empirical antibiotic treatment of CAP



- When no improvement is seen after two courses of antibiotics in the primary care setting, it is advised to consult an expert (internist-infectiologist, microbiologist or pulmonologist).
- Macrolides should not be used as initial therapy in mild CAP. They can be used in the event of penicillin allergy and when doxycycline cannot be used due to pregnancy or lactation. If doxycycline is given, start with a loading dose of 200 mg.
- In the event of penicillin allergy in moderately severe CAP, administer a 2nd or 3rd generation cephalosporin or moxifloxacin.
- High-level resistance to penicillin should be considered in patients not – or insufficiently – responding to empirical treatment with penicillin or amoxicillin and with a recent travel history abroad. In such patients increasing the dosage of penicillin (2 million IU 6 dd, or continuous infusion) or a switch to a cephalosporin (e.g. ceftriaxone 2 g once daily) should be considered.
- In the event of aspiration, the possibility of anaerobes or *Enterobacteriaceae* should be taken into account: penicillin or cephalosporins are replaced by amoxicillin-clavulanate.
- In the case of fulminant pneumonia after an episode of influenza, penicillin is replaced by a beta-lactam antibiotic with activity against *S. aureus*.
- In patients with moderately severe or severe CAP with documented colonisation of the respiratory tract with *Pseudomonas* spp., ceftazidime or ciprofloxacin should be added if not otherwise given.
- Antiviral treatment with oseltamivir is recommended for patients with confirmed or suspected influenza who have complicated illness with respiratory insufficiency (please refer to the guidelines from the National Institute for Public Health and Environment 'LCI richtlijn influenza', 2011).
- The recommended treatment options for severe CAP on the ICU are considered to be two equally acceptable choices.
- *Legionella* pneumonia should be treated with a fluoroquinolone. Most evidence is available for levofloxacin.
- De-escalate empirical antibiotic therapy when clinically improved or definitive microbiological diagnosis is made. Please also refer to SWAB Guidelines for Antimicrobial Stewardship, 2017.



**Table 3.** Guidelines for the choice of initial therapy for community-acquired pneumonia

Severity	Antibiotic	Route	Dose	Frequency
<b>Category I: mild pneumonia</b>				
1st choice	Amoxicillin	Oral	750 mg	q8h
2nd choice	Doxycycline	Oral	100 mg (first dose 200 mg)	q24h
<b>Category II: moderately severe pneumonia</b>				
	Penicillin	IV	1 MU	q6h
	Amoxicillin	IV	1000 mg	q6h
<b>Category III: severe pneumonia (ward)</b>				
Monotherapy	Cefuroxime	IV	1500 mg	q8h
	or Ceftriaxone	IV	2000 mg	q24h
	or Cefotaxime	IV	1000 mg	q6h
<b>Category IV: severe pneumonia (ICU)</b>				
Monotherapy	Moxifloxacin	IV / oral	400 mg	q24h
Combination therapy	Cefuroxime	IV	1500 mg	q8h
	or Ceftriaxone	IV	2000 mg	q24h
	or Cefotaxime	IV	1000 mg	q6h
	and Ciprofloxacin	IV	400 mg	q12h

monotherapy with regard to 90-day mortality.<sup>9</sup> However, these data also indicated that Gram-negative bacteria and *S. aureus* are a more frequent cause of CAP among patients on the ward admitted with severe CAP when compared with patients with moderately severe CAP (CAP-START study, unpublished data) and, therefore, these pathogens should be covered in empirical therapy. Especially in patients with severe CAP, *Legionella* infection can be reliably ruled out with the urinary antigen test. To summarise, the recommendations for the empirical antibiotic therapy of the following four categories of CAP are as follows (table 3, figure 1):

**Risk category I (mild CAP): CURB-65: 0-1, PSI: 1-2, non-hospitalised**

For this group, initial therapy with a narrow spectrum beta-lactam antibiotic (1st choice) or doxycycline (2nd choice) is recommended. This is in accordance with the previous guidelines<sup>1</sup> and the 2011 guidelines for patients treated by GPs.<sup>33</sup> Doxycycline is not a first choice for this group in view of the 9% resistance of *S. pneumoniae* against doxycycline. The choice of a drug active against the most frequently occurring causative agent (*S. pneumoniae*) is essential in this case. Oral penicillin is not considered a first choice in view of the suboptimal gastrointestinal resorption. As a result of the increasing resistance of

pneumococci against macrolides (10-14%), monotherapy with macrolides is discouraged unless the patient is allergic to penicillin and it is not possible to administer doxycycline (e.g. because of pregnancy or lactation). In that case, either clarithromycin or azithromycin are preferred. If there is a strong clinical suspicion of *Legionella* infection, then the *Legionella* urine antigen test must be carried out and empirical therapy must be adjusted. For patients in risk category I who receive amoxicillin or penicillin as initial therapy but do not improve within 48 hours, therapy should be switched to monotherapy with a macrolide or doxycycline. If therapy was initiated with doxycycline a switch to macrolides is not rational. In that case, referral to a hospital must be considered.<sup>1</sup> In the outpatient setting, coverage for *S. aureus* in the influenza season, e.g. by amoxicillin-clavulanate, is not indicated.

**Risk category II (moderate-severe CAP): CURB-65: 2, PSI: 3-4, admitted to non-ICU ward**

For this category, initial therapy should be beta-lactam monotherapy, and the first choice is either intravenous penicillin or amoxicillin. Doxycycline and macrolides cannot be recommended because of the increasing pneumococcal resistance. Broad-spectrum antibiotics such as amoxicillin-clavulanate, cefuroxime, ceftriaxone or cefotaxime are not recommended because the expected

pathogens do not justify the broader spectrum. In case of penicillin allergy, the best alternatives are a 2nd or 3rd generation cephalosporin or a 4th generation quinolone. If a patient of category II has one or more of the following risk factors for *Legionella* spp. a Legionella antigen test should be performed within 24 hours: 1) a recent visit to a foreign country, 2) coming from an epidemic setting of *Legionella* spp. infections, 3) failure to improve despite  $\geq 48$  hours of treatment with a beta-lactam antibiotic at an adequate dosage without evidence of abnormal absorption or non-compliance. If the Legionella antigen test is positive, therapy must be switched to monotherapy directed against *Legionella* spp. For Legionella pneumonia, levofloxacin has the most clinical evidence to support its use.

**Risk category III (severe CAP): CURB-65: 3-5, PSI: 5, admitted to non-ICU ward**

Therapy should be started with a 2nd or 3rd generation cephalosporin, because of the higher incidence of Gram-negative bacteria, and to a lesser extent *S. aureus*, in this patient group. For all patients in category III, a Legionella and pneumococcal urinary antigen test should be carried out as a routine procedure within 12-24 hours of admission. If the Legionella test is positive, monotherapy directed against *Legionella* spp. is recommended. If the pneumococcal urinary antigen test is positive, therapy can be narrowed to penicillin or amoxicillin. If both are negative, therapy should be continued with a 2nd or 3rd generation cephalosporin.

**Risk category IV (severe CAP): admission to ICU**

In this category, it is always recommended to cover *S. pneumoniae*, *Legionella* spp., *S. aureus* and Gram-negative bacteria. For this purpose there are two equally acceptable choices, both with excellent antimicrobial activity against all the expected causative agents. The choice is dependent, on the one hand, on the risk of development of antimicrobial resistance at the population level; on the other hand, the costs, the ease of administration and the profile of side effects play an important role:

- Monotherapy with moxifloxacin or
- Combination therapy with a 2nd or 3rd generation cephalosporin and ciprofloxacin.

Moxifloxacin is preferred over levofloxacin because of its high activity against pneumococci, favourable pharmacodynamic characteristics and good tissue penetration. Potential prolongation of the QT interval should be taken into account. Because of the high rate of side effects associated with their intravenous administration, macrolides are no longer recommended in this patient category.

For all patients in category IV, a Legionella urinary antigen and *S. pneumoniae* urine antigen test is carried out as a routine procedure within 12-24 hours of admission. If the Legionella test is positive, monotherapy directed against *Legionella* spp. is recommended. If the Legionella test is negative, the patient is still treated further with combination therapy (coverage of both *S. pneumoniae* and *Legionella* spp.) because the sensitivity of the urinary antigen test is not 100%. Since the specificity of the pneumococcal urine antigen test is  $< 100\%$ , antibiotic treatment can be streamlined to penicillin or amoxicillin only in patients with a positive test result and without other pathogens detected if clinical stability (often within 48 hours) has been reached, or pneumococci have been cultured. In the event of a culture-proven causative agent, pathogen-directed antibiotic treatment is to be preferred at all times.

**TIMING OF FIRST DOSE OF ANTIBIOTICS, TREATMENT DURATION AND SWITCH FROM INTRAVENOUS TO ORAL ROUTE**

This section has not been altered compared with the 2011 guidelines.<sup>1</sup> All patients should receive antibiotics as soon as the diagnosis of CAP is established. For patients with severe CAP admitted through the emergency department (ED), the first antibiotic dose should be administered within four hours of presentation and preferably while still in the ED. In patients with sepsis and septic shock, the recommendation of the Surviving Sepsis Campaign guidelines applies.<sup>34</sup> Although the guidelines emphasise the importance of initiating antibiotic treatment rapidly, maximal efforts should be made to avoid inaccurate diagnosis of CAP and/or inappropriate utilisation of antibiotics.

If adult patients with mild to moderate-severe CAP are treated with a beta-lactam antibiotic or fluoroquinolones, the length of antibiotic treatment can be shortened to five days in those patients who have substantially improved after three days of treatment.<sup>35-37</sup> Pneumonia caused by *S. aureus* should be treated for at least 14 days.<sup>25</sup> Pneumonia caused by *M. pneumoniae* or *Chlamydia* spp. is generally treated for 14 days,<sup>25</sup> but no studies on treatment duration have been performed for these agents. For Legionella pneumonia a treatment duration of 7-10 days is sufficient in patients with a good clinical response.

Patients should be switched from intravenous to oral therapy when they have substantially improved clinically, have adequate oral intake and gastrointestinal absorption



and are haemodynamically stable.<sup>38,39</sup> For patients who fulfil these criteria, inpatient observation after switching to oral therapy is not needed.<sup>25,40</sup>

## THE ROLE OF ADJUNCTIVE CORTICOSTEROIDS FOR PATIENTS WITH CAP

Over the last decade a whole range of potential immunomodulating therapies as adjunctive to antibiotics have been investigated in patients with CAP. Most data are available on the potential efficacy of corticosteroids. The three largest studies on adjunctive therapy with corticosteroids in patients with CAP<sup>5,41,42</sup> yielded statistically significantly faster defervescence and, thereby, a shorter time to clinical stability and/or a shortening of length of hospital stay by one day for patients treated with corticosteroids. However, symptom resolution, overall cure rates, complication rates, ICU admission and mortality did not differ between patients with or without corticosteroid treatment. In all studies, the risk of hyperglycaemia was significantly higher in the corticosteroid-treated patients. In addition, treatment with short-term, high-dose corticosteroids may lead to other side effects, once applied routinely in larger populations. Therefore, the guidelines committee concluded, based on the available data, that the relatively small short-term benefits of adjunctive corticosteroids do not outweigh the potential disadvantages. As a result, the guidelines do not recommend corticosteroids as adjunctive therapy for treatment of CAP.

## ACKNOWLEDGMENT

The Guidelines Committee would like to thank all individuals and societies who contributed to the development of these guidelines.

## DISCLOSURES

Members of the preparatory committee reported the following potential conflicts of interest:

MJB: Novartis Europe advisory board Daptomycin, Pfizer Netherlands advisory board vaccines, grant from Pfizer Netherlands for investigating aetiology of CAP; WGB: received a grant from GSK and Astra Zeneca for research and a fee from Pfizer for medical advice; EMWG: grant from GSK for investigating aetiology of CAP; TJV: received two grants for research and a fee for consultation from Pfizer; APES: received support for conference attendance from Pfizer and AstraZeneca.

The other authors have no competing interests.

## REFERENCES

- Wiersinga WJ, Bonten MJ, Boersma WG, et al. SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. *Neth J Med*. 2012;70:90-101.
- Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. *N Engl J Med*. 2014;370:543-51.
- Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. *Lancet*. 2015;386:1097-108.
- Graffelman AW, Knuistingh NA, le Cessie S, Kroes AC, Springer MP, van den Broek PJ. Pathogens involved in lower respiratory tract infections in general practice. *Br J Gen Pract*. 2004;54:15-9.
- Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2011;377:2023-30.
- Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. *Thorax*. 1995;50:543-7.
- Van Vught LA, Scicluna BP, Wiewel MA, et al. Comparative Analysis of the Host Response to Community-acquired and Hospital-acquired Pneumonia in Critically Ill Patients. *Am J Respir Crit Care Med*. 2016;194:1366-74.
- Van de Veerdonk FL, Kolwijck E, Lestrade PP, et al. Influenza-Associated Aspergillosis in Critically Ill Patients. *Am J Respir Crit Care Med*. 2017 Apr 7. doi: 10.1164/rccm.201612-2540LE. [Epub ahead of print]
- Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. *N Engl J Med*. 2015;372:1312-23.
- Nethmap 2016, SWAB, Bergen, 2016 ([www.swab.nl](http://www.swab.nl))
- Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med*. 1997;336:243-50.
- Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax*. 2003;58:377-82.
- Bont J, Hak E, Hoes AW, Macfarlane JT, Verheij TJ. Predicting death in elderly patients with community-acquired pneumonia: a prospective validation study reevaluating the CRB-65 severity assessment tool. *Arch Intern Med*. 2008;168:1465-8.
- Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. *Thorax*. 2010;65:878-83.
- Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. *Am J Med*. 2005;118:384-92.
- Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. *Thorax*. 2006;61:419-24.
- Huijts SM, van Werkhoven CH, Boersma WG, et al. Guideline adherence for empirical treatment of pneumonia and patient outcome. Treating pneumonia in the Netherlands. *Neth J Med*. 2013;71:502-7.
- Boersma WG, Daniels JM, Lowenberg A, Boeve WJ, van de Jagt EJ. Reliability of radiographic findings and the relation to etiologic agents in community-acquired pneumonia. *Respir Med*. 2006;100:926-32.
- Kauppinen MT, Lahde S, Syrjala H. Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumoniae. *Arch Intern Med*. 1996;156:1851-6.
- Claessens YE, Debray MP, Tubach F, et al. Early Chest Computed Tomography Scan to Assist Diagnosis and Guide Treatment Decision for Suspected Community-acquired Pneumonia. *Am J Respir Crit Care Med*. 2015;192:974-82.
- Hagaman JT, Rouan GW, Shipley RT, Panos RJ. Admission chest radiograph lacks sensitivity in the diagnosis of community-acquired pneumonia. *Am J Med Sci*. 2009;337:236-40.
- Writing Committee of the WHO CoCAoPI, Bautista E, Chotpitayasunondh T, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. *N Engl J Med*. 2010;362:1708-19.

23. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Recomm Rep.* 2010;59:1-62.
24. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax.* 2009;64 Suppl 3:i11-55.
25. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis.* 2007;44 Suppl 2:S27-S72.
26. Lettinga KD, Verbon A, Weverling GJ, et al. Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy. *Emerg Infect Dis.* 2002;8:1448-54.
27. Yzerman EP, Den Boer JW, Lettinga KD, Schellekens J, Dankert J, Peeters M. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands. *J Clin Microbiol.* 2002;40:3232-6.
28. Gutierrez F, Masia M, Rodriguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of *Streptococcus pneumoniae* urinary antigen in a prospective study of community-acquired pneumonia in Spain. *Clin Infect Dis.* 2003;36:286-92.
29. Sordé R, Falcó V, Lowak M, et al. Current and Potential Usefulness of Pneumococcal Urinary Antigen Detection in Hospitalized Patients With Community-Acquired Pneumonia to Guide Antimicrobial Therapy. *Arch Intern Med.* 2011;171:166-72.
30. Roson B, Fernandez-Sabe N, Carratala J, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. *Clin Infect Dis* 2004;38:222-6.
31. Stralin K, Kaltoft MS, Konradsen HB, Olcen P, Holmberg H. Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia. *J Clin Microbiol.* 2004;42:3620-5.
32. Andreo F, Ruiz-Manzano J, Prat C, et al. Utility of pneumococcal urinary antigen detection in diagnosing exacerbations in COPD patients. *Respir Med.* 2010;104:397-403.
33. Verheij T, Hopstaken RM, Prins JM, et al. NHG-standaard Acute hoesten. Eerste herziening. *Huisarts en Wetenschap.* 2011;54:68-92.
34. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med.* 2017;43:304-77.
35. File TM, Jr., Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. *J Antimicrob Chemother.* 2007;60:112-20.
36. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. *J Antimicrob Chemother.* 2004;54:515-23.
37. El Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. *BMJ.* 2006;332:1355.
38. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. *BMJ.* 2006;333:1193.
39. Schuts EC, Hulscher ME, Mouton JW, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. *Lancet Infect Dis.* 2016;16:847-56.
40. Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. *Am J Med.* 2006;119:512-7.
41. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet.* 2015;385:1511-8.
42. Sniijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blind clinical trial. *Am J Respir Crit Care Med.* 2010;181:975-82.
43. Everdingen JJE, Burgers JS, Assendelft WJJ, et al. Evidence-based richtlijnontwikkeling. Een leidraad voor de praktijk. Houten: Bohn Stafleu van Loghum; 2004.